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Hydroxychloroquine sulfate is one of an extensive series of 4-aminoquinolines with
antimalarial activity. Moreover, it is used for the treatment of rheumatoid arthritis.
Sometimes, hydroxychloroquine sulfate is beneficial for the treatment of autoimmune
diseases. Based on recent clinical experiments, it is exploited for the treatment of
COVID-19, coronavirus across the globe. The chromatogram separation was achieved
by using Agilent, Zorbax C8, 250mm × 4.6mm i.d., column. The buffer consists
of 0.01M of 1-pentane sulfonic acid and 0.02% of orthophosphoric acid in purified
water. Mixed buffer, acetonitrile, and methanol (800:100:100 v/v). The flow rate was
1.0ml min−1, and injection volume was 10 µl. Detection was made at 254 nm
by using a dual absorbance detector (DAD). The reversed-phase high-performance
liquid chromatography (RP-HPLC) method has been developed and validated as per
the current International Conference on Harmonization (ICH) guidelines to estimate
hydroxychloroquine sulfate tablets. As part of method validation, specificity, linearity,
precision, and recovery parameters were verified. The concentration and area
relationships were linear (R2 > 0.999) over the concentration range of 25–300 µg
ml−1 for hydroxychloroquine (HCQ). The relative standard deviations for precision and
intermediate precision were <1.5%. The proposed RP-HPLC generic method was
applied successfully to evaluate the in vitro dissolution profile with different pH conditions
such as 0.1N HCl, pH 4.5 acetate buffer, and pH 6.8 phosphate buffers as US-marketed
reference products.
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INTRODUCTION
Hydroxychloroquine (HCQ) is a white crystalline powder,
chemically named 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-
ethylamino]ethanol. It is easily soluble in water and organic
solvents. HCQ is mainly used as a medication for malaria
and a wide variety of inflammatory conditions. Moreover,
HCQ has in vitro activity for the treatment of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) and related
coronaviruses problems (Colson et al., 2020; Wang et al., 2020;
Yao et al., 2020). In recent days, it is proven to have the
superficial ability and tolerable safety against coronavirus disease
2019 (COVID-19)-related pneumonia in clinical experiments
performed in China (Gao et al., 2020) and other parts of the
world. COVID-19, which appeared in the middle of December
2019, has proliferated swiftly, now confirmed in numerous
countries. As of September 25, 2020, COVID-19 has produced
32,475,585 infections and 987, 754 deaths in all countries majorly
in the USA, India, Brazil, Russia, and other countries across
the globe.
After conductingmultiple clinical trials by the State Council of
China, it confirmed that chloroquine phosphate, a long-standing
medicine used for malaria treatment, had proven noticeable
efficacy and satisfactory safety in treating COVID-19-related
pneumonia patients. Serious unfavorable reactions to HCQ and
chloroquine phosphate were not observed in the COVID-19
patients. Based on these conclusions, a conference was organized
on February 15, 2020; members including professionals and
FIGURE 1 | Chemical structure of Hydroxy chloroquine sulfate.










Trail-1 Acetonitrile and water (50:50) 50 1.0 Early elution and peak tailing
Trail-2 Acetonitrile and water (30:70) 50 1.0 Early elution and peak tailing
Trail-3 Methanol:Water (50:50) 50 1.2 Peak tailing and less plate count
Trail-4 Methanol:Water (20:80) 50 1.2 Peak tailing and broad peak
Trail-5 Acetonitrile:Methanol:Water (30:20:50) 30 0.8 Peak split and early elution
Trail-6 Acetonitrile:Methanol:Buffer (20:20:60) 30 1.0 Early elution and peak tailing
Trail-7 Acetonitrile:Methanol:Buffer (10:10:80) 10 1.0 Suitable peak
HCQ samples (220.0 µg/ml) were analyzed in HPLC equipment using a C8 column, with UV detection fixed at 254 nm, at 30◦C.
HCQ, hydroxychloroquine; HPLC, high-performance liquid chromatography.
experts from government and regulatory authorities of clinical
trials agreed and approved that HCQ and chloroquine phosphate
are effective against COVID-19. Based upon limited available
clinical trial data, HCQ recommends the treatment of COVID-
19-infected patients in most countries. Due to the wider
accessibility of these HCQ tablets in the United States, it has been
administered to hospitalized COVID-19 patients. It is still under
clinical investigation trials to treat patients with different stages
such as mild, moderate, and severe COVID-19. The chemical
structure of HCQ is shown in Figure 1.
Currently, most countries were looking for HCQdrug product
literature and other related information for better understanding
due to the COVID 19 pandemic. It is essential to know
the drug product release with respective time in in vitro
conditions. The literature survey revealed that different types
of analytical techniques were used for the determination of
HCQ, such as high-performance liquid chromatography (HPLC)
with photodiode array (PDA) detector (Volin, 1995; Zuluaga-
Idárraga et al., 2014), HPLC with UV detector (Akintonwa et al.,
1983; Morris, 1985; Brown et al., 1986; Tonnesen et al., 1988;
Croes et al., 1994), chromatography-tandem mass spectrometry
(MS/MS) (Wang et al., 2012; Füzéry et al., 2013), liquid
chromatography (LC)/ion trap (IT)/MS (Dongre et al., 2009),
capillary-LC (Chaulet et al., 1993), and electrochemical study
(Arguelho et al., 2003).
Majority of the literature was reported in the
pharmacokinetics of HCQ in biological fluids. The United States
Pharmacopeia (USP) monograph method was reported with a
UV-Spectro photometric technique for the estimation of HCQ
tablets in vitro dissolution profile. Generally, the UV methods’
results are not reliable due to the lack of reproducibility. Other
than the USP method, there was no literature on HCQ tablet’s in
vitro dissolution profile in different multimedia to understand
the product behavior. The reversed-phase (RP)-HPLC is a
powerful and simple technique for quantification of drug
products in different pH conditions.
Moreover, the regulated pharmaceutical industry released
products into the global market after determining quality,
safety, and efficacy. Hence, HPLC methods are required
with suitable precision, accuracy, and sensitivity level.
The present work’s main aim is to develop a simple
and reproducible HPLC method for estimation of HCQ
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The Agilent HPLC 1260 Infinity-II was used for the estimation
of HCQ dissolution profile. It consists of four channels,
pressure range up to 600 bar, degasser with an integrated
purge valve, thermostatic sampler, and column compartment.
The PDA detector connected to empower 3 software (Build
3471 SPs Installed: Feature Release 3 DB ID: 2639633283)
to monitor the output signal. The Disteck Premiere 5100
model dissolution apparatus was used to perform the
multimedia profile. The column is Agilent Zorbax C8,
250mm × 4.6mm i.d., 5µm. Sartorius analytical balances
were used for the weighing of standards and samples. Bio-
Technics ultra sonicator is used to extract the drug from the
sample matrix.
Materials and Reagents
The HCQ with certified purity of 99.2% was obtained from SCI
pharma, Taiwan. AR grade ortho phosphoric acid, hydrochloric
acid, potassium dihydrogen phosphate, 1-pentane sulfonic
acid, NaOH, sodium acetate, and acetic acid chemicals were
purchased from VWR chemicals, Radnor, PA, USA. HPLC-grade
acetonitrile (99.9%) andmethanol from J. T. Baker were procured
from VWR chemicals, Radnor, PA, USA. High-quality HPLC-
grade purified water was used throughout the experiments.
Chromatographic and Dissolution
Conditions
The chromatogram separation was achieved by using Agilent,
Zorbax C8 (250 × 4.6mm i.d.) 5.0µm column with a simple
isocratic method. The buffer consists of 0.01M of 1-pentane
sulfonic acid and 0.02% orthophosphoric acid in purified water.
Mixed buffer, acetonitrile, and methanol (800:100:100 v/v). The
flow rate was 1.0ml min−1, and injection volume was 10 µl.
Detection was made at 254 nm by using a dual absorbance
detector (DAD). The dissolution conditions media volume
900ml, USP-II (Paddle), and 50 rpm were used to perform
the profile.
Preparation of Dissolution Media Buffer
To prepare acidic medium, 8.5ml of concetration HCl (35%) into
1,000ml of volumetric flask and made up to volume with water.
For pH 4.5 sodium acetate buffer, weighed and transferred 2.99 g
of sodium acetate (NaC2H3O2.3H2O) into a 1,000-ml volumetric
flask added 14ml 2N acetic acid (CH3COOH) and made up to
volume with water. We prepared pH 6.8 phosphate buffer by
TABLE 2 | System suitability results.
S. No. Name of the parameter Observed
value
1 The USP Tailing factor of HCQ, peak
from standard chromatogram
1.21
2 %RSD for peak area of HCQ for five
replicate injections
0.24
3 The USP Theoretical plates of HCQ
peak from standard chromatogram
5,568
%RSD, % relative SD; HCQ, hydroxychloroquine; USP, United States Pharmacopeia.
TABLE 3 | Precision, intermediate precision (RSD), and accuracy of the HPLC











100.0 99.3 ± 1.15 1.16 1.05 99.3
200.0 200.8 ± 0.38 0.19 0.52 100.4
300.0 300.4 ± 0.85 0.28 0.63 100.1
aRSD = (SD/mean * 100); baccuracy = (experimental concentration/theoretical
concentration) × 100.
HCQ, hydroxychloroquine; HPLC, high-performance liquid chromatography; RSD,
relative SD.
FIGURE 2 | Typical Chromatogram of Hydroxy chloroquine sulfate standard.
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mixing 250ml of 0.2Mmonobasic potassium phosphate solution
and 112ml of 0.2M NaOH into 1,000ml volumetric flask and
made up to volume with water.
Dissolution Conditions and Preparation of
Sample
To evaluate the dissolution profile of HCQ reference listed
product [Reference Listed Drug (RLD)] (Plaquenil) with USP
apparatus-II (Paddle) having 50 rpm and 900ml of medium
maintained 37.0◦C temperature. After dropping the RLD tablets
into six individual dissolution vessels, we collected the samples
at different time points 5, 10, 15, 20, 30, 45, and 60min and
injected into HPLC. The equal concentration of HCQ standard




The current study’s main aim is to develop a simple and rapid
HPLC method for the estimation of HCQ dissolution profile in
different media. During the initial method, development scanned
HCQ standard solution in PDA detector observed maximumUV
absorption was observed at 254 nm; hence, this wavelength was
fixed to optimize other chromatographic conditions. The major
changes in the chromatographic conditions tested were explained
in Table 1. The initial mobile phase compositions containing
water and acetonitrile provided low HCQ interaction with the
Zorbax column, resulting in rapid drug elution. Similarly, mobile
phases containing a higher percentage of acetonitrile resulted
in early HCQ elution (<1min), showing peak with insufficient
symmetry factors and plate count. HCQ is an easily water-
soluble compound, which presents a pKa equal to 4–5. At
pH below this value, HCQ molecule polarity is diminished,
offering better drug interaction with C8 column. In this way,
1-pentane sulfonic acid and phosphoric acid solution were
used as the buffered solvent, producing improved results. The
buffer, methanol, and acetonitrile mixture at 800:100:100 (v/v)
offered the most satisfactory HCQ peak separation with suitable
retention time (3.1min; Figure 2). The flow rate of HPLC
was set to 1.0ml min−1, and the injection volume was 10
µl. The evaluated system suitability parameters are retention
TABLE 4 | Dissolution profile of HCQ RLD and in-house formulation results.
Time pH 4.5 Acetate buffer pH 6.8 Phosphate buffer 0.1N HCl
Reference In-house Reference In-house Reference In-house
% % RSD % % RSD % % RSD % % RSD % % RSD % % RSD
5 min 25 36 45 18.4 19 37.6 30 16.4 23 23.9 29 14.1
10 min 60 21.3 78 8.8 50 17.3 55 16.6 51 17.2 57 16.5
15 min 80 13.8 88 6.8 75 12.1 71 15.8 73 14 75 13.1
20 min 90 7.7 93 4 88 5.9 80 13.8 85 10 86 8.7
30 min 96 3.2 94 3 94 2.6 86 11.5 92 3.6 93 3.9
45 min 97 2.1 96 2.4 95 1.6 87 10.1 94 1.2 97 1.8
60 min 97 1.6 97 2 95 1.6 89 9.1 94 1.2 98 1.2
Recovery 98 1.2 98 1.7 96 1.9 98 1.2 95 0.9 98 1.2
HCQ, hydroxychloroquine; RLD, Reference Listed Drug; RSD, reference SD.
FIGURE 3 | Graph model comparison of HCQ dissolution profile of Reference Vs In House.
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time, tailing factor, and theoretical plates with optimized
conditions (Table 2).
Method Validation
The method validation was performed as per the current
International Conference on Harmonization (ICH) guidelines.
As part of method validation, specificity, linearity, precision, and
recovery parameters were verified.
Specificity
Specificity is a significant parameter. Here, the optimized
test method conditions are intended to estimate HCQ drug
release from solid oral dosage formulations. We performed
the specificity of the method by injecting the blank and
placebo samples individually. We have evaluated the interference
of unwanted peaks at the retention time of HCQ. The
results show there was no interference at the retention
time of the HCQ peak; hence, the optimized method is
specific for the estimation of HCQ drug release in the
dissolution profile.
Linearity
To perform the method’s linearity, prepared a series
of concentrations to range from 25 to 300 µg ml−1
of HCQ. The calibration curve was plotted for peak
areas and concentration of HCQ standard solution. The
concentration and area relationships were linear (R2 >
0.999) over the concentration range of 25–300 µg ml−1
for HCQ.
Precision
To evaluate the current optimized method’s precision, prepared
six sample solutions individually from the same pharmaceutical
formulation were analyzed consecutively. The repeatability of the
method was proven by calculating the six samples % relative
standard deviation (%RSD). In the current method, the %RSD
of six samples was found <2.0. In the similar way performed
intermediate precision with different analysts, different days, and
different dissolution apparatus, the %RSD of six samples was
found <2.0.
Accuracy
The method’s accuracy was carried out measuring the
pharmaceutical samples fortified with a known quantity of
the analytes. Spiked the known amount of HCQ at three
different concentration levels (50, 100, and 150%) to placebo
solution. Each concentration level was prepared in triplicate and
calculated the recovery of each sample and RSD. The recovery
results were between 97.0 to 103.0%, and RSD values were
<2.0% (Table 3). The recovery values proved that the method
allows direct determination of HCQ in tablet formulation in the
presence of other excipients.
Solution Stability
The solution stability was performed at benchtop conditions.
Prepared two samples as per the optimized method and kept
on the benchtop for about 48 h. It was evaluated every 12 h
with a freshly prepared standard solution. The HCQ sample
solution was stable at benchtop for about 48 h. The samples
were filtered through 0.45 µ nylon and polyvinylidene fluoride
(PVDF) filters, there was no difference between the filtered and
unfiltered samples.
Application of the Method
The proposed RP-HPLC generic method was applied to analyze
US-marketed products successfully and performed in vitro
dissolution profile for the RLD and in-house formations to
compare the product release with the respective specified time
intervals. To complete the dissolution profile, we selected
three different media such as 0.1N HCl, pH 4.5 acetate
buffer, pH 6.8 phosphate buffer to understand the product
behaviors in low to high pH conditions. The results were
shown different drug release pattern up to the first 15–
20min. After that, all the media reached optimum release
(Table 4, Figure 3).
CONCLUSION
HCQ is currently recommended for the treatment of hospitalized
COVID-19 patients in most of the countries in the world. It is
essential to understand the drug profiling in vitro conditions;
hence, a simple HPLC method has been developed successfully
for estimation of the HCQ dissolution profile in in vitro
conditions. The optimized HPLC method is used for the
estimation of the dissolution profile of RLD and in-house tablets.
The optimized method was validated as per the ICH guidelines,
and the results were found satisfactory. Finally, the developed
method was used in the quality control lab for the analysis
of dissolution.
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